BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
See today's BioWorld
Home
» Abcuro’s KLRG1-targeting programs attract $42M in new funding round
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Abcuro’s KLRG1-targeting programs attract $42M in new funding round
Jan. 7, 2021
By
Cormac Sheridan
No Comments
Abcuro Inc. raised $42 million in a series A-1 round to progress preclinical programs in autoimmune disease and cancer involving a largely overlooked immune checkpoint receptor, killer cell lectin-like receptor G1 (KLRG1).
BioWorld
Financings
Cancer
Series A